


REMARKS

Pursuant to 37 C.F.R. § 1.121, attached as an appendix is a version with markings to show changes made to the claims.

Applicants respectfully acknowledge the June 23, 2003, personal interview with Examiner Coleman. In response to suggestions made by Examiner Coleman during the interview, claims 31, 32, 80, and 81 have been amended to correct various informalities.

Respectfully submitted;

Date: July 23, 2003



Michael L. Goldman
Registration No. 30,727

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1304
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
<u>July 25, 2003</u> Date	<u>Jo Ann Whalen</u> Jo Ann Whalen

APPENDIX
Version With Markings to Show Changes Made
Page 1 of 5

In reference to the amendments, additions appear as double-underlined text, while deletions appear as bracketed text, as indicated below:

Please amend claims 31, 32, 80, and 81 as follows:

31. (Twice Amended) A compound according to claim 1, selected from the group consisting of the following compounds:

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸
[1.]	Me	H	H	Me	H	H	H	H
[2.]	Me	H	H	Me	H	OMe	H	H
[3.]	Me	H	H	Me	H	F	H	H
[4.]	Me	H	H	Me	F	H	H	H
[5.]	Me	H	H	Me	F	F	H	H
[6.]	Me	H	H	Me	Me	F	H	H
[7.]	Me	H	H	Me	Cl	F	H	H
[8.]	Me	H	H	Me	Cl	H	H	H
[9.]	Me	H	H	Me	H	Me	H	H
[10.]	Me	H	H	Me	F	Me	H	H
[11.]	Me	H	H	Me	H	Cl	H	H
[12.]	Me	H	H	Me	F	Cl	H	H
[13.]	Me	H	H	Me	Cl	Cl	H	H
[14.]	Me	H	H	Et	H	H	H	H
[15.]	Me	H	H	Et	F	F	H	H
[16.]	Me	H	H	F	H	OMe	H	H
[17.]	Me	H	H	F	F	OMe	H	H
[18.]	Me	H	H	F	F	Me	H	H
[19.]	Me	H	H	F	F	Cl	H	H
[20.]	Me	H	H	F	F	F	H	H
[21.]	Me	H	H	F	Cl	H	H	H
[22.]	Me	H	H	CN	H	H	H	H
[23.]	Me	H	H	CF ₃	H	H	H	H
[24.]	Me	Me	H	Me	H	H	H	H
[25.]	Me	H	Me	Me	H	H	H	H
[26.]	Me	H	F	Me	H	H	H	H
[27.]	Me	H	Me	F	H	H	H	H
[28.]	Me	H	OMe	Me	H	H	H	H
[29.]	Me	H	OH	Me	H	H	H	H
[30.]	Me	H	H	OCF ₃	H	H	H	H
[31.]	Me	H	H	OMe	F	F	H	H
[32.]	Me	H	H	OMe	Me	F	H	H
[33.]	Me	H	H	OMe	F	Me	H	H
[34.]	Me	H	H	OMe	Me	H	H	H
[35.]	Me	H	H	O(Ph)	H	H	H	H

APPENDIX
Version With Markings to Show Changes Made
Page 2 of 5

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸
[36.]	Me	H	H	O(4-OmePh)	H	H	H	H
[37.]	Me	H	H	O(CH ₂ Ph)	H	H	H	H
[38.]	Me	H	H	OH	Me	H	H	H
[39.]	Me	H	H	OH	F	Me	H	H
[40.]	Me	H	H	OH	Me	F	H	H
[41.]	Me	H	H	OH	F	F	H	H
[42.]	Me	H	Me	H	H	H	H	H
[43.]	Me	H	Me	H	H	F	H	H
[44.]	Me	H	Me	H	F	F	H	H
[45.]	Me	H	Me	H	F	H	F	H
[46.]	Me	H	Me	H	F	H	H	H
[47.]	Me	H	Me	H	Me	F	H	H
[48.]	Me	H	Me	H	Cl	F	H	H
[49.]	Me	H	Me	H	Cl	Cl	H	H
[50.]	Me	H	Me	H	Cl	H	H	H
[51.]	Me	H	Me	H	H	Cl	H	H
[52.]	Me	H	Me	H	F	Cl	H	H
[53.]	Me	H	Me	H	H	OMe	H	H
[54.]	Me	H	Me	H	H	CN	H	H
[55.]	Me	H	Me	H	H	CF ₃	H	H
[56.]	Me	H	Me	H	H	Me	H	H
[57.]	Me	H	CH ₂ NHMe	H	H	H	H	H
[58.]	Me	H	CH ₂ OH	H	H	H	H	H
[59.]	Me	H	SO ₂ NH ₂	H	H	H	H	H
[60.]	Me	H	SO ₂ NHMe	H	H	H	H	H
[61.]	Me	H	OMe	H	H	Me	H	H
[62.]	Me	H	OMe	H	F	H	F	H
[63.]	Me	H	OMe	H	Cl	H	H	H
[64.]	Me	H	OMe	H	Cl	Cl	H	H
[65.]	Me	H	OMe	H	F	Cl	H	H
[66.]	Me	H	OMe	H	Cl	F	H	H
[67.]	Me	H	H	Me	F	H	F	H
[68.]	Me	H	H	Me	F	H	Cl	H
[69.]	Me	Me	H	Me	F	H	F	H
[70.]	Me	H	H	Me	F	F	F	H
[71.]	Et	H	H	Me	H	F	H	H
[72.]	Me	H	F	CH ₂ Me	H	H	H	H
[73.]	Me	H	H	CH ₂ NH ₂	H	H	H	H
[74.]	Me	H	H	CH ₂ NHMe	H	H	H	H
[75.]	Me	H	OH	CN	H	H	H	H
[76.]	Me	H	H	CH ₂ OH	H	H	H	H

APPENDIX
Version With Markings to Show Changes Made
Page 3 of 5

32. (Twice Amended) A compound according to claim 1, wherein the enantiomer is selected from the group consisting of the following compounds:

	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>
[1.]	H	H	Me	F
[2.]	OMe	H	F	F
[3.]	Me	H	F	F
[4.]	H	H	Cl	F
[5.]	H	H	F	F
[6.]	Me	F	H	F
[7.]	Me	H	F	H
[8.]	Me	H	H	F ₂

80. (Amended) The compound according to claim 51, selected from the group consisting of the following compounds:

	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>	<u>R⁵</u>	<u>R⁶</u>	<u>R⁷</u>	<u>R⁸</u>
[1.]	Me	H	H	Me	H	OMe	H	H
[2.]	Me	H	H	Me	H	F	H	H
[3.]	Me	H	H	Me	F	H	H	H
[4.]	Me	H	H	Me	F	F	H	H
[5.]	Me	H	H	Me	Me	F	H	H
[6.]	Me	H	H	Me	Cl	F	H	H
[7.]	Me	H	H	Me	Cl	H	H	H
[8.]	Me	H	H	Me	H	Me	H	H
[9.]	Me	H	H	Me	F	Me	H	H
[10.]	Me	H	H	Me	H	Cl	H	H
[11.]	Me	H	H	Me	F	Cl	H	H
[12.]	Me	H	H	Me	Cl	Cl	H	H
[13.]	Me	H	H	Et	H	H	H	H
[14.]	Me	H	H	Et	F	F	H	H

APPENDIX
Version With Markings to Show Changes Made
Page 4 of 5

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸
[15.]	Me	H	H	F	H	OMe	H	H
[16.]	Me	H	H	F	F	OMe	H	H
[17.]	Me	H	H	F	F	Me	H	H
[18.]	Me	H	H	F	F	Cl	H	H
[19.]	Me	H	H	F	F	F	H	H
[20.]	Me	H	H	F	Cl	H	H	H
[21.]	Me	H	H	CN	H	H	H	H
[22.]	Me	H	H	CF ₃	H	H	H	H
[23.]	Me	Me	H	Me	H	H	H	H
[24.]	Me	H	Me	Me	H	H	H	H
[25.]	Me	H	F	Me	H	H	H	H
[26.]	Me	H	Me	F	H	H	H	H
[27.]	Me	H	H	O(Ph)	H	H	H	H
[28.]	Me	H	H	O(4-OmePh)	H	H	H	H
[29.]	Me	H	H	O(CH ₂ Ph)	H	H	H	H
[30.]	Me	H	Me	H	H	F	H	H
[31.]	Me	H	Me	H	F	F	H	H
[32.]	Me	H	Me	H	F	H	F	H
[33.]	Me	H	Me	H	F	H	H	H
[34.]	Me	H	Me	H	Me	F	H	H
[35.]	Me	H	Me	H	Cl	F	H	H
[36.]	Me	H	Me	H	Cl	Cl	H	H
[37.]	Me	H	Me	H	Cl	H	H	H
[38.]	Me	H	Me	H	H	Cl	H	H
[39.]	Me	H	Me	H	F	Cl	H	H
[40.]	Me	H	Me	H	H	OMe	H	H
[41.]	Me	H	Me	H	H	CN	H	H
[42.]	Me	H	Me	H	H	CF ₃	H	H
[43.]	Me	H	Me	H	H	Me	H	H
[44.]	Me	H	CH ₂ NHMe	H	H	H	H	H
[45.]	Me	H	CH ₂ OH	H	H	H	H	H

APPENDIX
Version With Markings to Show Changes Made
Page 5 of 5

	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶	R ⁷	R ⁸
[46.]	Me	H	SO ₂ NH ₂	H	H	H	H	H
[47.]	Me	H	SO ₂ NHMe	H	H	H	H	H
[48.]	Me	H	H	Me	F	H	F	H
[49.]	Me	H	H	Me	F	H	Cl	H
[50.]	Me	Me	H	Me	F	H	F	H
[51.]	Me	H	H	Me	F	F	F	H
[52.]	Et	H	H	Me	H	F	H	H
[53.]	Me	H	F	CH ₂ Me	H	H	H	H
[54.]	Me	H	H	CH ₂ NH ₂	H	H	H	H
[55.]	Me	H	H	CH ₂ NHMe	H	H	H	H
[56.]	Me	H	H	CH ₂ OH	H	H	H	H ₂

81. (Amended) The compound according to claim 51, wherein the enantiomer is selected from the group consisting of the following compounds:

	<u>R¹</u>	<u>R²</u>	<u>R³</u>	<u>R⁴</u>
[1.]	Me	H	F	F
[2.]	Me	F	H	F
[3.]	Me	H	F	H
[4.]	Me	H	H	F ₂